Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Применение диуретиков у пациентов с артериальной гипертонией и метаболическими нарушениями - Журнал Системные Гипертензии №1 (2008)
Применение диуретиков у пациентов с артериальной гипертонией и метаболическими нарушениями
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Anti-hypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967–75.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Anti-hypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Anti-hypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
3. Hansson L, Lindholm LH, Niskanen L et al. 611-616. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. Lancet 1999; 353: 611–6.
4. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed) 1985; 291: 97–104.
5. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64.
6. Semenchenko M. Drugs and prescribing in Russia: the challenges of transition. Internat J Risk Safety Med 1998; 11.
7. Hogerzeil HV, Barnes KI, Henning RH et al. Geneva. World Health Organization-Department of Essential Drugs and Medicines Policy. 2001.
8. Петрова Г.И. Мониторинг национальной лекарственной политики – результаты сравнения по странам региона – Болгария, Румыния, Македония, Босния-Герцеговина. Центр. Евр. журн. по обществен. здравоохранению. 2001; 9: 205–15.
9. Mandal SC. Study of rational drug use profiles in an Non-Government Organization-Managed Health Center versus Private Health Practitioners. Improving use of medicines: Abstracts of second international conference. Thailand. 2004; 39.
10. Wright JM, Cheng-Han Lee, Chambers KC. Systematic review of antihypertensive therapies: Does the evidence assist in choosing a first-line drug? Canad Med Assoc J 1999; 161 (1): 25–32.
11. Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. American J Cardiol 1996; 77 (6): 12B–16B.
12. British national formulary, №51, march, 2006.
13. Elisaf MS, Theodorou J, Pappas H et al. Effectiveness and metabolic effects of perindopril and diuretics combination in primary hypertension. J Hum Hypertens 1999; 13 (11): 787–91.
14. Malini PL, Strocchi E, Ricci C, Ambrosioni E. Indapamide or hydrochlorothiazide in hypertensive patients resistant to treatment with an angiotensin-converting enzyme inhibitor. CURR THER RES CLIN EXP 1994; 55(8): 932–7.
15. Elliott WJ, Weber RR, Murphy MB. A double-blind, randomized, placebo-controlled comparison of the metabolic effects of low-dose hydrochlorothiazide and indapamide. J Clin Pharmacol 1991; 31 (8): 751–7.
16. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Anti-hypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Anti-hypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
3. Hansson L, Lindholm LH, Niskanen L et al. 611-616. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. Lancet 1999; 353: 611–6.
4. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed) 1985; 291: 97–104.
5. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64.
6. Semenchenko M. Drugs and prescribing in Russia: the challenges of transition. Internat J Risk Safety Med 1998; 11.
7. Hogerzeil HV, Barnes KI, Henning RH et al. Geneva. World Health Organization-Department of Essential Drugs and Medicines Policy. 2001.
8. Петрова Г.И. Мониторинг национальной лекарственной политики – результаты сравнения по странам региона – Болгария, Румыния, Македония, Босния-Герцеговина. Центр. Евр. журн. по обществен. здравоохранению. 2001; 9: 205–15.
9. Mandal SC. Study of rational drug use profiles in an Non-Government Organization-Managed Health Center versus Private Health Practitioners. Improving use of medicines: Abstracts of second international conference. Thailand. 2004; 39.
10. Wright JM, Cheng-Han Lee, Chambers KC. Systematic review of antihypertensive therapies: Does the evidence assist in choosing a first-line drug? Canad Med Assoc J 1999; 161 (1): 25–32.
11. Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. American J Cardiol 1996; 77 (6): 12B–16B.
12. British national formulary, №51, march, 2006.
13. Elisaf MS, Theodorou J, Pappas H et al. Effectiveness and metabolic effects of perindopril and diuretics combination in primary hypertension. J Hum Hypertens 1999; 13 (11): 787–91.
14. Malini PL, Strocchi E, Ricci C, Ambrosioni E. Indapamide or hydrochlorothiazide in hypertensive patients resistant to treatment with an angiotensin-converting enzyme inhibitor. CURR THER RES CLIN EXP 1994; 55(8): 932–7.
15. Elliott WJ, Weber RR, Murphy MB. A double-blind, randomized, placebo-controlled comparison of the metabolic effects of low-dose hydrochlorothiazide and indapamide. J Clin Pharmacol 1991; 31 (8): 751–7.
16. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
Авторы
О.Н.Ткачева, А.Ю.Галяутдинова
Кафедра клинической фармакологии и фармакотерапии Московского государственного
медико-стоматологического университета
Кафедра клинической фармакологии и фармакотерапии Московского государственного
медико-стоматологического университета
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.